Drug intelligence / Profile preview

Episcleral Estradiol Analog

Development stage: Preclinical
Lead developer: 3T Ophthalmics
Modality: Small Molecules
Administration: Ophthalmic

Overview

Episcleral Estradiol Analog is a small molecule estrogen receptor agonist/modulator being developed by Targeted Therapy Technologies (3T Ophthalmics). The drug is designed to provide neuroprotection for traumatic and neurodegenerative ocular conditions. It utilizes a proprietary delivery system consisting of a sequestered transscleral, controlled-release episcleral reservoir. This technology is intended to provide sustained therapeutic levels of the estradiol analog directly to the posterior segment of the eye via transscleral diffusion, minimizing systemic exposure and the need for frequent intravitreal injections. The program is currently in the preclinical stage of development.

Other names: Estradiol analog

Targets

ESR2 (ERβ)ESR1 (ERα)

Beyond the preview

Go deeper on Episcleral Estradiol Analog.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Episcleral Estradiol Analog.

Explore the full profile